Slide 1: Earnings Call – Q1 2022
Earnings Call – Q1 2022 May 5, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
2©2022 ViewRay Technologies, Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this presentation that are not purely historical are forward-lookin
Slide 3: What we achieved – financial results Q1 2022
3©2022 ViewRay Technologies, Inc. All rights reserved. What we achieved – financial results Q1 2022 Q1 2022 Q1 2021 Change MRIdian orders 7 7 - MRIdian backlog $330.9M $264.3M 25% Revenue $18.9M $15.5M 22% Cash use $35.2M $28.1M +7m (1) Excluding net proceeds from equity offering. (1)
Slide 4: MRIdian therapy adoption accelerating
4©2022 ViewRay Technologies, Inc. All rights reserved. Thousands of patients with clinically reported outcomes. MRIdian therapy adoption accelerating 2021 Future (~3 years) 18k 48 2x (again) 4x (again) Driving rapid growth and therapy adoption 4k 24 Then (3 years ago) Systems installed(1) Patients T
Slide 5: Clear line of sight to >100 MRIdian installations
5©2022 ViewRay Technologies, Inc. All rights reserved. Install stage 10 Clear line of sight to >100 MRIdian installations Further enhanced by growing commercial pipeline Installed systems 50 Systems backlog 60 MRIdian Programs 120= Accelerating robust commercial pipeline ~ ~
Slide 6: Strategic clarity. Execution excellence.
6©2022 ViewRay Technologies, Inc. All rights reserved. Innovation • MIRAGE • SCIMITAR • SMART Pancreas data having an impact Clinical • MRIdian A3i • Improved throughput • Brain treatment package • Enhanced ease of use Innovation • Accelerating breadth and depth of pipeline Commercial Strategic clar
Slide 7: Patient awareness initiatives gaining traction
7©2022 ViewRay Technologies, Inc. All rights reserved. Patient awareness initiatives gaining traction
Slide 8: Strategy accelerating results
8©2022 ViewRay Technologies, Inc. All rights reserved. Strategy accelerating results ViewRay strategy MRIdian value Customer results Multi- dimensional strategy Clinical evidence Innovation advancements Commercial pipeline Patient awareness Clinical Strategic Economic Customers are buying multiple M
Slide 9: Successful MRIdian programs driving adoption
9©2022 ViewRay Technologies, Inc. All rights reserved. Successful MRIdian programs driving adoption Similar markets • California • Northeast • France • Italy • UK … growing list of MSA’s/countries Florida Denver, CO Atlanta, GA S. America Future programActive program
Slide 10: Sustainable, high-quality, long-term revenue growth
10©2022 ViewRay Technologies, Inc. All rights reserved. Sustainable, high-quality, long-term rev. growth 7 Q1 22 MRIdian System orders ~$80M Future contractual revenue Estimated revenue per system System revenue $6M Estimated recurring rev. $6M = Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Aggregate ~$8
Slide 11: In 2022… Delivering P&L leverage
11©2022 ViewRay Technologies, Inc. All rights reserved. In 2022… Meaningful operating expense leverage Placements will drive 750 - 1,000 bps of gross margin improvement On track to deliver ~40% revenue growth Well capitalized: sufficient cash on hand to drive to cash flow breakeven Delivering P&L le
Slide 12: Financial Results Q1 2022
>} vIEWRAY Financial Results Qi 2022
Slide 13: What we achieved – financial results Q1 2022
13©2022 ViewRay Technologies, Inc. All rights reserved. What we achieved – financial results Q1 2022 (1) Excluding net proceeds from equity offering. (2) Inclusive of increase in restricted cash related to a customer deposit. Q1 2022 Q1 2021 Change MRIdian orders 7 7 - MRIdian backlog $330.9M $264.3
Slide 14: Path to cash flow breakeven
14©2022 ViewRay Technologies, Inc. All rights reserved. Path to cash flow breakeven 3. Effective operating expense and working capital management 2. Cost down measures: product and process driven 1. Accelerating system placements to drive leverage Benefits realized starting in ‘22 and accelerate int
Slide 15: @ VIEW RAY | VISIBLY BETTER
@ VIEW RAY | VISIBLY BETTER